Spinraza™showed very promising results at all steps of the clinical development and was approved by US Food and Drug Administration (FDA) on December 23, 2016. Spinraza™is the first FDA-approved treatment for SMA and the first antisense drug to restore expression of a fully functional protein via splicing correction.